Heartseed株式会社 Logo

Heartseed株式会社

Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.

219A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区芝浦1丁目2番3号シーバンスS館5階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Heartseed Inc. is a clinical-stage biotechnology company specializing in regenerative medicine for cardiac diseases. Founded in 2015 as a spin-off from Keio University, the company develops iPSC-derived cell therapies for severe heart failure. Its core strategy is "remuscularization," a novel approach to regenerate damaged heart tissue by transplanting highly purified cardiomyocyte spheroids. The lead pipeline product, HS-001, is an allogeneic iPSC-derived cardiomyocyte therapy administered via intramyocardial injection for patients with heart failure with reduced ejection fraction (HFrEF). Heartseed aims to provide a fundamental treatment for conditions where heart transplantation was previously the only curative option. The company also conducts research on next-generation therapies using autologous and HLA-edited iPSCs to minimize immune rejection.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Heartseed株式会社 and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-19 09:00
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-06-12 08:30
Regulatory News Service
確認書
Japanese 8.0 KB
2025-06-12 08:30
Interim Report
半期報告書-第10期(2024/11/01-2025/12/31)
Japanese 143.9 KB
2025-01-27 02:01
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 02:01
Regulatory News Service
確認書
Japanese 8.0 KB
2025-01-27 02:00
Annual Report
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 6.0 MB
2025-01-27 02:00
Regulatory News Service
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 21.1 KB
2024-07-22 08:18
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-07-11 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-06-26 08:00
Prospectus
有価証券届出書(新規公開時)
Japanese 9.0 MB

Automate Your Workflow. Get a real-time feed of all Heartseed株式会社 filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Heartseed株式会社 via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France BIM
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark BIOPOR
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea 086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France ALBIO
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland BIOV

Talk to a Data Expert

Have a question? We'll get back to you promptly.